| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Stoke Therapeutics, Inc. (STOK) has 15 insiders with recent SEC Form 4 filings, including 0 buys and 27 sells. STOK is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 3.91M | $123.83M | - | |
| CEO | 380.0K | $12.05M | - | |
| Dir | 283.3K | $8.98M | - | |
| Other | 118.7K | $3.76M | - | |
| Dir | 110.9K | $3.51M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2021 | Liau Gene | EVP Research &Preclinical Dev | Sale+OE | 5,344 | $62.93 | $336,297.16 | -7.4% | |
| Mar 1, 2021 | Levin Arthur A | Director | Sale+OE | 12,500 | $60.79 | $759,841.14 | -71.6% | |
| Feb 23, 2021 | Tulipano Stephen J | CFO | Sale+OE | 30,000 | $58.86 | $1,765,895.79 | -70.9% | |
| Feb 19, 2021 | Tzianabos Arthur74 | Director | Sale+OE | 10,000 | $60.67 | $606,652.00 | -100% | |
| Jan 6, 2021 | Nash Huw M.81 | COO &Cbo | Sale+OE | 5,732 | $58.96 | $337,985.41 | -46.8% | |
| Dec 21, 2020 | Ticho Barry52 | Chief Medical Officer | Sale+OE | 1,365 | $57.62 | $78,654.05 | -0.3% | |
| Dec 18, 2020 | Kaye Edward M. Md47 | CEO | Sell | 25,000 | $60.00 | $1,500,000.00 | -82.8% | |
| Dec 18, 2020 | Nash Huw M.81 | COO &Cbo | Sale+OE | 50,000 | $60.00 | $3,000,000.00 | -100% | |
| Dec 1, 2020 | Nash Huw M.81 | COO &Cbo | Sale+OE | 5,700 | $49.84 | $284,079.62 | -59.5% | |
| Nov 27, 2020 | Kaye Edward M. Md47 | CEO | Sell | 12,152 | $50.00 | $607,600.00 | -32.7% |